News

Read about the progress of individual NINDS PDBP projects and learn about presentations and workshops that are relevant to the PDBP.
Metabolic imaging patterns in posterior cortical atrophy and Lewy body dementia.

  • Gupta V
  • Verma R
  • Ranjan R
  • Belho ES
  • Seniaray N
  • Dinand V
  • Malik D
  • Mahajan H
Kynurenines, Neuropsychiatric Symptoms, and Cognitive Prognosis in Patients with Mild Dementia.

  • Hafstad Solvang SE
  • Nordrehaug JE
  • Aarsland D
  • Lange J
  • Ueland PM
  • McCann A
  • Midttun Ø
  • Tell GS
  • Giil LM
Multicenter Alzheimer's and Parkinson's disease immune biomarker verification study.

  • Brosseron F
  • Kolbe CC
  • Santarelli F
  • Carvalho S
  • Antonell A
  • Castro-Gomez S
  • Tacik P
  • Namasivayam AA
  • Mangone G
  • Schneider R
  • Latz E
  • Wüllner U
  • Svenningsson P
  • Sánchez-Valle R
  • Molinuevo JL
  • Corvol JC
  • Heneka MT
  • AETIONOMY study group.
Submentalis REM Sleep Muscle Activity: A Potential Biomarker for Synucleinopathy.

  • McCarter SJ
  • Feemster JC
  • Tabatabai GM
  • Sandness DJ
  • Timm PC
  • McCarter AR
  • Talley HN
  • Junna MR
  • Savica R
  • Singer W
  • Coon EA
  • Benarroch EE
  • Josephs KA
  • Boeve BF
  • Silber MH
  • St Louis EK
The effect of levodopa on saccades - Oxford Quantification in Parkinsonism study.

  • Lu Z
  • Buchanan T
  • Kennard C
  • FitzGerald JJ
  • Antoniades CA
Transcranial sonography in atypical parkinsonism: How reliable is it in real clinical practice? A multicentre comprehensive study.

  • Alonso-Canovas A
  • Tembl Ferrairó JI
  • Martínez-Torres I
  • Lopez-Sendon Moreno JL
  • Parees-Moreno I
  • Monreal-Laguillo E
  • Pérez-Torre P
  • Toledano Delgado R
  • García Ribas G
  • Sastre Bataller I
  • Masjuan J
  • Martinez-Castrillo JC
  • Walter U
Longitudinal intracortical diffusivity changes in de-novo Parkinson's disease: A promising imaging biomarker.

  • Sampedro F
  • Martínez-Horta S
  • Marín-Lahoz J
  • Pagonabarraga J
  • Kulisevsky J
REM sleep without atonia as prodromal marker of Lewy body disease: Fake news or the real deal?

  • Rodrigues LD
  • Oliveira LF
  • Scorza CA
  • Andersen ML
  • Tufik S
  • Finsterer J
  • Scorza FA
Intracellular and Intercellular Mitochondrial Dynamics in Parkinson's Disease.

  • Valdinocci D
  • Simões RF
  • Kovarova J
  • Cunha-Oliveira T
  • Neuzil J
  • Pountney DL
Diffusion Tensor MRI to Distinguish Progressive Supranuclear Palsy from α-Synucleinopathies.

  • Spotorno N
  • Hall S
  • Irwin DJ
  • Rumetshofer T
  • Acosta-Cabronero J
  • Deik AF
  • Spindler MA
  • Lee EB
  • Trojanowski JQ
  • van Westen D
  • Nilsson M
  • Grossman M
  • Nestor PJ
  • McMillan CT
  • Hansson O
4-Repeat tau seeds and templating subtypes as brain and CSF biomarkers of frontotemporal lobar degeneration.

  • Saijo E
  • Metrick MA 2nd
  • Koga S
  • Parchi P
  • Litvan I
  • Spina S
  • Boxer A
  • Rojas JC
  • Galasko D
  • Kraus A
  • Rossi M
  • Newell K
  • Zanusso G
  • Grinberg LT
  • Seeley WW
  • Ghetti B
  • Dickson DW
  • Caughey B
Testing the 2018 NIA-AA research framework in a retrospective large cohort of patients with cognitive impairment: from biological biomarkers to clinical syndromes.

  • Carandini T
  • Arighi A
  • Sacchi L
  • Fumagalli GG
  • Pietroboni AM
  • Ghezzi L
  • Colombi A
  • Scarioni M
  • Fenoglio C
  • De Riz MA
  • Marotta G
  • Scarpini E
  • Galimberti D
Dietary Polyphenols: A Multifactorial Strategy to Target Alzheimer's Disease.

  • Dhakal S
  • Kushairi N
  • Phan CW
  • Adhikari B
  • Sabaratnam V
  • Macreadie I
Hospitalization, Alzheimer's and Related Neuropathologies, and Cognitive Decline.

  • James BD
  • Wilson RS
  • Capuano AW
  • Boyle PA
  • Shah RC
  • Lamar M
  • Ely EW
  • Bennett DA
  • Schneider JA

Press releases, workshop summaries, and editorials

Accelerating Research for Parkinson’s Disease

The Accelerating Medicines Partnership Parkinson's disease (AMP PD) program, launched on Jan 30, 2018, is the most ambitious initiative so far to find a cure for Parkinson's disease. Formed by the US National Institutes of Health (NIH), the US Food and Drug Administration (FDA), five biopharmaceutical and life science companies, and the Michael J. Fox Foundation, this partnership is focused on discovering novel therapeutic targets and on developing biomarkers to help validate existing therapeutic targets for Parkinson's disease.

AMP PD

 

NIH launches partnership to improve success of clinical trials for patients with Parkinson’s disease

“Advancing treatments for Parkinson’s disease is hampered by insufficient understanding of biological networks; drugs aimed at seemingly promising therapeutic targets fail in clinical trials,” said NIH Director Francis S. Collins, M.D., Ph.D. “By combining our expertise and resources, AMP PD partners hope to increase our collective odds of success in accelerating the development of effective treatments for a million Americans who suffer from this debilitating disease.”